SCHEDULE 13G/A: Soleus Capital Entities Disclose 5.1% Passive Stake in Essa Pharma, Inc.

Soleus Capital Master Fund, L.P. and related entities have filed an amended Schedule 13G/A, reporting a passive beneficial ownership of 5.1% in Essa Pharma, Inc.'s common stock as of December 31, 2024.

Summary

• Soleus Capital Master Fund, L.P., along with its related entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and individual Guy Levy, collectively reported beneficial ownership of 2,262,026 shares of Essa Pharma, Inc. common stock.
• This aggregate ownership represents 5.1% of Essa Pharma, Inc.'s outstanding common stock.
• The percentage is calculated based on 44,388,550 shares of common stock outstanding as of December 16, 2024, as reported in Essa Pharma, Inc.'s Annual Report on Form 10-K.
• Soleus Capital Special Opportunities Fund, L.P. reported 0 shares beneficially owned.
• The filing is an Amendment No. 7 to a previously filed Schedule 13G, indicating an update to an existing ownership position.
• The reporting persons certify that the securities were acquired and are held for investment purposes and not with the intent to change or influence the control of Essa Pharma, Inc., confirming a passive investment stance.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a 13G/A is a factual filing, the disclosure of a significant passive stake by an institutional investor can be viewed as a vote of confidence in the company, even without active engagement.

Positives

• The disclosure of a 5.1% passive stake by institutional investors like Soleus Capital Master Fund, L.P. can signal confidence in Essa Pharma, Inc.'s long-term prospects, even if passive.

Risks

• The reporting persons disclaim beneficial ownership of the shares held by Soleus Capital Master Fund, L.P. for any purpose other than determining their obligations under Section 13(d) of the Exchange Act, which clarifies their limited responsibility for the shares.

Future Outlook

This document does not provide any forward-looking statements or guidance regarding Essa Pharma, Inc.'s future operations or financial performance, as it is a beneficial ownership disclosure.

Industry Context

This filing is a standard disclosure in the investment industry, indicating that a significant institutional investor has acquired or maintained a passive stake above the 5% threshold in a publicly traded company. Such filings are common and provide transparency regarding major shareholders.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 5.1% stake could be viewed positively, potentially indicating long-term confidence in the company's value, although the investment is passive.

Key Dates

Keywords

Essa Pharma Inc., Soleus Capital Master Fund, Schedule 13G/A, Beneficial Ownership, Common Stock, Investment Fund, Passive Investment, SEC Filing, Institutional Investor, Equity Stake